Explore the frontier
Filter every story, video, company, game and lab experiment by topic, disease area, technology, company, development stage, format and audience.
75 results
BreakthroughsA Drug That Works in Cells Isn’t a Cure: How to Read a Biotech Breakthrough
Killing diseased cells in a dish is the easy part of drug development. This guide explains the evidence ladder, why most candidates fail, and seven questions to ask before believing a breakthrough headline.
Genome + CellsDecode the Genome: What Sequencing Can Tell Us—and What It Cannot
From the $3 billion Human Genome Project to routine sequencing, reading DNA has become easy. Here is what a genome can reveal today, and where uncertain variants, risk scores and missing context set hard limits.
Genome + CellsGene Editing, Gene Therapy, and RNA Medicines: Three Different Ways to Change an Outcome
In December 2023 the FDA approved Casgevy, the first CRISPR-based therapy, for sickle cell disease. Here is how gene editing, gene therapy and RNA medicines differ, and what that approval does and doesn't prove.
LongevityThe Cell Health Frontier: Senescence, Mitochondria, and the Search for Better Healthspan
Some problems of ageing may start inside individual cells. This explainer tours senescence and mitochondria, from striking mouse results to small, mixed human trials, and explains why no therapy is yet approved to treat ageing.
LongevityCan We Slow Aging? A Field Guide to Evidence, Hype, and Hard Questions
Longevity claims are everywhere, but human evidence is thin. This field guide sorts the most popular anti-ageing ideas by what has been shown in animals, what has been tested in people, and what nobody knows yet.
BreakthroughsInside a Clinical Trial: What Phase 1, 2, and 3 Results Really Mean
A positive Phase 1 result and a positive Phase 3 result sound similar but mean very different things. Here is what each stage of a clinical trial is designed to show, and what it cannot.
Companies + StocksThe Biotech Startup Map: How Young Companies Move From Discovery to Patients
Many biotech startups spend years building evidence rather than selling products. This map traces the stations most pass through, from licensing a discovery to the forks where companies partner, sell, go public or stop.
Companies + StocksHow to Research a Biotech Stock Without Confusing a Great Story With Great Evidence
Biotech companies tell two stories at once: one scientific, one financial. This educational guide, which is not investment advice, shows how to check primary sources like SEC EDGAR, ClinicalTrials.gov and FDA databases.
DeepTech + MedTechThe Next Medical Device Wave: Sensors, Robotics, Imaging, and Intelligent Software
From over-the-counter glucose monitors to AI-enabled imaging software, medical devices are getting smaller, smarter and more autonomous. Here is what is authorized, what is still experimental, and what could slow things down.
DeepTech + MedTechBioprinting Human Tissue: What Works in the Lab, and What Would It Take to Reach Patients?
No bioprinted solid organ has been transplanted into a person, but bioprinting has produced striking lab and animal results. Here is what works today, what has reached early human testing, and what still stands in the way.
DeepTech + MedTechOrganoids and Lab-Grown Models: Could They Improve How We Test Treatments?
Organoids and organ-on-a-chip systems let researchers test drugs on human tissue models before people. The early evidence is promising but specific, and the models still miss much of real human biology.
Companies + StocksFrom University Lab to Startup: How Medical Discoveries Become Products
Most medical products begin as university research, then pass through tech transfer offices, licences or spinouts, and the regulatory system. This guide maps each step and the reasons discoveries stall.